Deep Brain Stimulation in Parkinson`s Disease Market Report 2026

The deep brain stimulation in parkinson’s disease market size has grown strongly in recent years. It will grow from $3.27 billion in 2025 to $3.49 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing prevalence of Parkinson’s disease, growing adoption of DBS devices, rising awareness of advanced neuromodulation therapies, expansion of neurosurgical infrastructure, and increasing healthcare spending.

The deep brain stimulation in parkinson’s disease market size is expected to see strong growth in the next few years. It will grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rising demand for personalized neuromodulation therapies, growing investments in research and clinical trials, increasing access to tele-neurology services, expansion of reimbursement coverage, and rising adoption of MRI-compatible and rechargeable devices. Major trends in the forecast period include technological advancements in closed-loop and directional stimulation, innovations in rechargeable and long-life IPGs, developments in AI-assisted DBS programming, research and development in minimally invasive surgical techniques, and advancements in remote monitoring and telemedicine capabilities.

The rising number of Parkinson’s disease patients is expected to propel the growth of the deep brain stimulation in Parkinson’s disease market going forward. Parkinson’s disease is a progressive neurological disorder that affects movement, causing symptoms such as tremors, stiffness, slowness of movement, and impaired balance due to the degeneration of dopamine-producing neurons in the brain. The rise in the number of Parkinson’s disease patients is due to the aging population, as the risk of developing Parkinson’s disease increases significantly with age. Deep brain stimulation helps manage Parkinson’s disease by delivering targeted electrical impulses to specific brain regions, reducing motor symptoms, improving quality of life, and lowering dependence on long-term medication. For instance, in 2025, according to the Parkinson’s Foundation, a US-based non-profit organization, an estimated 1.1 million people in the United States are living with Parkinson’s disease, expected to rise to 1.2 million by 2030, with nearly 90,000 new diagnoses each year and more than 10 million people affected worldwide. Therefore, the rising number of Parkinson’s disease patients is driving the growth of the deep brain stimulation in Parkinson’s disease market.

The increasing healthcare expenditure is expected to drive the growth of the deep brain stimulation in Parkinson’s disease sector in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The rise in healthcare spending is largely due to the growing prevalence of chronic diseases, which necessitate long-term and expensive treatments. Higher healthcare expenditure supports deep brain stimulation in Parkinson’s disease by funding advanced surgical procedures, medical equipment, and follow-up care. It enhances patient outcomes by expanding access to this effective therapy, which alleviates motor symptoms and improves quality of life. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, reflecting a 0.9% rise compared to 2022. Consequently, the rising healthcare expenditure is fueling the growth of the deep brain stimulation in Parkinson’s disease sector.

Leading companies in the deep brain stimulation for Parkinson's disease sector are concentrating on developing advanced technologies, such as miniaturizing rechargeable implantable pulse generators and incorporating remote programming platforms, to improve patient comfort and accessibility to care. Miniaturizing rechargeable implantable pulse generators involves designing these battery-powered neurostimulation devices in smaller, thinner forms, allowing for less invasive implantation while still delivering consistent therapeutic electrical pulses over extended periods. For example, in January 2024, Abbott Laboratories, a US-based multinational medical devices and healthcare company, introduced its Liberta RC DBS system. This platform is a miniaturized rechargeable deep brain stimulation system with remote programming functionality, aimed at treating individuals with movement disorders such as Parkinson's disease and essential tremor. The system also offers the longest recharge interval among FDA-approved DBS devices, requiring only 10 recharge sessions annually for most patients, and leverages the NeuroSphere Virtual Clinic to enable patients to connect with their doctors and receive treatment adjustments from home.

Major companies operating in the deep brain stimulation in parkinson`s disease market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Mayo Foundation for Medical Education and Research, Cleveland Clinic, Renishaw plc, Neuralink Corp., NeuroPace Inc., PINS Medical Co. Ltd., Neurosoft Ltd., BrainsWay Ltd., Medscape, Inomed Medizintechnik GmbH, SceneRay Corporation Ltd., Neuroelectrics Barcelona S.L., Soterix Medical Inc., CorTec GmbH, Aleva Neurotherapeutics SA, NeuroSigma Inc., BrainGate Company Inc.

North America was the largest region in the deep brain stimulation in parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deep brain stimulation in parkinson`s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deep brain stimulation in parkinson`s disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have influenced the deep brain stimulation market by increasing the cost of imported electrodes, implantable pulse generators, and specialized surgical tools, leading to higher treatment costs in affected regions. the impact is most pronounced in segments such as implantable devices and surgical implantation services, particularly in north america and europe where imports are significant. while tariffs may create cost pressures, they also encourage local manufacturing and innovation in device efficiency, potentially fostering regional supply chain resilience and long-term market growth.

Deep brain stimulation in Parkinson’s disease is a medical intervention that involves implanting electrodes to deliver controlled electrical impulses to targeted regions of the brain. These impulses help alleviate motor symptoms such as tremors, rigidity, and slowed movements by modulating abnormal neural activity. It is usually suggested when medications are no longer effective in managing symptoms and seeks to enhance the overall quality of life for patients.

The key product types of deep brain stimulation in Parkinson’s disease include implantable pulse generators, electrodes and leads, external programmers, and accessories and consumables. Implantable pulse generators deliver controlled electrical impulses to targeted brain regions to regulate abnormal neural activity. Technologies include conventional, closed-loop, and wireless stimulation systems, supported by services such as evaluation, implantation, device programming, monitoring, maintenance, rehabilitation support, tele-neurology, and training programs. Applications include tremor management, rigidity, bradykinesia, and dyskinesia, used by hospitals, ambulatory surgical centers, and neurology clinics.

The deep brain stimulation in parkinson’s disease market consists of revenues earned by entities by providing services such as neurosurgical implantation procedures, preoperative patient assessment services, device programming and calibration services, postoperative monitoring and follow-up care, and long-term therapy management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The deep brain stimulation in parkinson’s disease market also includes sales of implantable neurostimulators, intracranial electrodes, extension leads, external programmers, and neurostimulation system accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.